Loading
Form preview
  • US Legal Forms
  • Other Templates
  • More Forms
  • More Multi-State Forms
  • Taiho Oncology Futibatinib (tas-120) Expanded Access Program (eap) Patient Access Form 2020

Get Taiho Oncology Futibatinib (tas-120) Expanded Access Program (eap) Patient Access Form 2020-2026

Futibatinib (TAS120) Expanded Access Program (EAP) Patient Access Forms form should be fully completed by the treating physician and submitted to: ExpandedAccess taihooncology.com Physicians Details (PLEASE.

How it works

  1. Open form

    Open form follow the instructions

  2. Easily sign form

    Easily sign the form with your finger

  3. Share form

    Send filled & signed form or save

How to fill out the Taiho Oncology Futibatinib (TAS-120) Expanded Access Program (EAP) Patient Access Form online

This guide provides a comprehensive overview of how to complete the Taiho Oncology Futibatinib (TAS-120) Expanded Access Program (EAP) Patient Access Form online. Following these instructions will ensure that all necessary information is accurately gathered for submission.

Follow the steps to successfully complete the Patient Access Form.

  1. Click the ‘Get Form’ button to access the Patient Access Form. This action will allow you to open the form for completion.
  2. Begin by entering the physician's details. Fill out the sections for first name, last name, work email address, work telephone number, institution, street/address, city, state, zip code, and medical license number. Ensure all fields are completed using capital letters as specified.
  3. Proceed to the delivery details section. Provide the pharmacist's details, including their first name, last name, work email address, work telephone number, pharmacist’s registration/license number, delivery address, and the name of the hospital or pharmacy.
  4. In the patient information section, enter the patient’s initials, sex, year of birth, weight, and height. Specify the intended treatment and clearly state the main reason for applying for the Expanded Access Program.
  5. Fill in the prior therapy section, detailing whether the patient has been intolerant or has clinically progressed on previous therapies. Provide a brief description as required.
  6. Complete the physician declaration section by acknowledging the unlicensed nature of the request, collecting personal data, and consenting to the processing of that data as outlined. Sign and date the form as indicated.
  7. Once all sections are completed and checked for accuracy, save changes to the form. You can then choose to download, print, or share the form for submission.

Take action now by completing the Taiho Oncology Futibatinib (TAS-120) Expanded Access Program Patient Access Form online.

Get form

Experience a faster way to fill out and sign forms on the web. Access the most extensive library of templates available.
Get form

Related content

Expanded Access Study of TAS-120 in Patients With...
See clinical trials of the intervention/treatment in this expanded access record. Official...
Learn more
Futibatinib Versus - Chemotherapy as ...
Sep 18, 2019 — Study TAS-120-301 is an open-label, multinational, parallel 2-arm...
Learn more
Expanded Access Study of TAS-120 in Patients With...
This is an open-label study to provide expanded access to TAS-120 prior to ... An...
Learn more

Related links form

IT/IS Inventory / IP Address Request Form - Esm Psu Where's That Phone?: Geolocating IP Addresses On 3G Networks The Advertiser Playbook - Peer39 Ipj Form

Questions & Answers

Get answers to your most pressing questions about US Legal Forms API.

Contact support

Patients in the study reported stable quality of life over nine months of treatment. Data supported U.S. Food and Drug Administration accelerated approval of LYTGOBI® (futibatinib) tablets in September 2022; continued approval may be contingent upon a confirmatory trial(s).

(“Taiho Oncology”), has been granted U.S. Food and Drug Administration (FDA) approval of futibatinib (Development code: TAS-120, U.S, Product Name: LYTGOBI®, Form: Tablets) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA) ...

The FDA granted priority review to futibatinib for treatment of certain patients with cholangiocarcinoma. The designation applies to use of the agent by previously treated patients with locally advanced or metastatic disease who harbor FGFR2 gene rearrangements, including gene fusions.

Futibatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Results: Between April 16, 2018, and November 29, 2019, a total of 103 patients were enrolled and received futibatinib. A total of 43 of 103 patients (42%; 95% confidence interval, 32 to 52) had a response, and the median duration of response was 9.7 months.

(“Taiho Oncology”), has been granted U.S. Food and Drug Administration (FDA) approval of futibatinib (Development code: TAS-120, U.S, Product Name: LYTGOBI®, Form: Tablets) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA) ...

classified in intrahepatic cholangiocarcinoma (iCCA), extrahepatic cho- langiocarcinoma, gallbladder cancer, and ampulla of Vater cancer.

Get This Form Now!

Use professional pre-built templates to fill in and sign documents online faster. Get access to thousands of forms.
Get form
If you believe that this page should be taken down, please follow our DMCA take down processhere.
Get Taiho Oncology Futibatinib (TAS-120) Expanded Access Program (EAP) Patient Access Form
Get form
  • Adoption
  • Bankruptcy
  • Contractors
  • Divorce
  • Home Sales
  • Employment
  • Identity Theft
  • Incorporation
  • Landlord Tenant
  • Living Trust
  • Name Change
  • Personal Planning
  • Small Business
  • Wills & Estates
  • Packages A-Z
  • Affidavits
  • Bankruptcy
  • Bill of Sale
  • Corporate - LLC
  • Divorce
  • Employment
  • Identity Theft
  • Internet Technology
  • Landlord Tenant
  • Living Wills
  • Name Change
  • Power of Attorney
  • Real Estate
  • Small Estates
  • Wills
  • All Forms
  • Forms A-Z
  • Other Templates
  • Legal Hub
  • About Us
  • Help Portal
  • Legal Resources
  • Blog
  • Affiliates
  • Contact Us
  • Delete My Account
  • Site Map
  • Industries
  • Forms in Spanish
  • Localized Forms
  • State-specific Forms
  • Forms Kit
  • Real Estate Handbook
  • All Guides
  • Notarize
  • Incorporation services
  • For Consumers
  • For Small Business
  • For Attorneys
  • USLegal
  • FormsPass
  • pdfFiller
  • signNow
  • altaFlow
  • DocHub
  • Instapage
Form Packages
  • Adoption
  • Bankruptcy
  • Contractors
  • Divorce
  • Home Sales
  • Employment
  • Identity Theft
  • Incorporation
  • Landlord Tenant
  • Living Trust
  • Name Change
  • Personal Planning
  • Small Business
  • Wills & Estates
  • Packages A-Z
Form Categories
  • Affidavits
  • Bankruptcy
  • Bill of Sale
  • Corporate - LLC
  • Divorce
  • Employment
  • Identity Theft
  • Internet Technology
  • Landlord Tenant
  • Living Wills
  • Name Change
  • Power of Attorney
  • Real Estate
  • Small Estates
  • Wills
  • All Forms
  • Forms A-Z
  • Other Templates
Customer Service
  • Legal Hub
  • About Us
  • Help Portal
  • Legal Resources
  • Blog
  • Affiliates
  • Contact Us
  • Delete My Account
  • Site Map
  • Industries
  • Forms in Spanish
  • Localized Forms
  • State-specific Forms
  • Forms Kit
Legal Guides
  • Real Estate Handbook
  • All Guides
Prepared for you
  • Notarize
  • Incorporation services
Our Customers
  • For Consumers
  • For Small Business
  • For Attorneys
Our Sites
  • USLegal
  • FormsPass
  • pdfFiller
  • signNow
  • altaFlow
  • DocHub
  • Instapage
Social Media
Call us now toll free:
+1 833 426 79 33
As seen in:
© Copyright 1999-2026 airSlate Legal Forms, Inc. 17 Station Street, Ste. 203, Brookline, MA 02445
  • Your Privacy Choices
  • Terms of Service
  • Privacy Notice
  • Content Takedown Policy
  • Bug Bounty Program